Research programme: mRNA-based therapeutics - CytomX Therapeutics/Moderna
Alternative Names: mRNA encoded masked IL-12 - CytomX Therapeutics/Moderna; mRNA-based therapeutics; mRNA-based therapeutics - CytomX Therapeutics/ModernaLatest Information Update: 07 May 2025
At a glance
- Originator CytomX Therapeutics; Moderna Therapeutics
- Class Antineoplastics; RNA
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 May 2025 Preclinical trials in Cancer in USA (Parenteral)
- 28 Apr 2025 Pharmacodynamics data from preclinical studies in Cancer released by CytomX Therapeutics
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)